A Study to Compare Two Surgical Procedures in Women with BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer (SOROCk)

Research Cycle:
Conduct Research

Lead Researcher:
Douglas A Levine, MD

Type of Research:
Cancer Screening and Prevention,Quality of Life

A Study to Compare Two Surgical Procedures in Women with BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer (SOROCk)

Study background

National expert guidelines recommend removal of the ovaries and fallopian tubes after childbearing is complete for women at high risk for ovarian cancer due to an inherited mutation. This surgery can lead to early-onset menopause and associated symptoms and side effects. Researchers believe that most ovarian cancers first begin in the fallopian tubes, suggesting that removing the fallopian tubes only may prevent the development of ovarian cancer.

Study aims

SOROCk [NRG-CC008] is a clinical trial studying if removal of just the fallopian tubes can reduce the risk of ovarian cancer nearly as much as removing both the ovaries and fallopian tubes among women with an inherited BRCA1 mutation. The main benefit of removing only the fallopian tubes and not the ovaries is to prevent surgically-induced menopause. The study will also exam various patient-reported quality of life outcomes. This concept has never been formally testing in a clinical trial.

FORCE and ABOUT Network role

FORCE advocates and staff have worked closely with researchers to provide input into the study design. FORCE championed for study development and approval by decision-makers at the National Cancer Institute. Now that the study is open and enrolling, FORCE will be actively promoting awareness and recruitment into the study. You can learn more about enrolling in the study on our SOROCk study detail page

"FORCE has played an important role in the development of research studies for the high-risk community. FORCE has championed research on less invasive methods to lower risk for cancer, such as studying the removal of fallopian tubes to lower risk for ovarian cancer." - Douglas Levine, MD, SOROCk Study Principal Investigator

This research is relevant for:

People who test positive for an inherited mutation

People at high risk for ovarian cancer